A Phase 3 interventional study of mRNA-1283.222 and mRNA-1273.222 in COVID-19, sponsored by ModernaTX, Inc.. Completed at 230 sites in 4 countries. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 3rd largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2023, is one of 6 in phase 3, and was the 18th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 10 · Phase 4 4
First in 2020; this study’s year is marked. 5 started in 2023.
This study's enrollment of 13,553 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 988 across the 22 interventional studies, 8,691 across the 12 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
4 of the studies in COVID-19 by Moderna, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
| NCT06189053ModernaTX, Inc.A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX) | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in COVID-19 by Moderna, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2).
Key Inclusion Criteria:
Part 2: No prior vaccination is required. For participants who have been previously vaccinated, proof of vaccination is required.
Key Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single intramuscular (IM) injection of mRNA-1283.222 on Day 1.
Biological: mRNA-1283.222
Participants will receive single IM injection of mRNA-1273.222 on Day 1.
Biological: mRNA-1273.222
Participants will receive single IM injection of mRNA-1283.815 on Day 1.
Biological: mRNA-1283.815
Participants will receive single IM injection of mRNA-1273.815 on Day 1.
Biological: mRNA-1273.815
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29
Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 103 arbitrary units (AU)/milliliter (mL) and ULOQ was 28571 AU/mL.
Time frame: Day 29
Part 1: Seroresponse Rate (SRR) Omicron BA.4/5 at Day 29
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL.
Time frame: Day 29
Part 1: GM of the Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) D614G at Day 29
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL.
Time frame: Day 29
Part 1: SRR of Ancestral SARS-CoV-2 D641G at Day 29
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 10 AU/mL and ULOQ was 111433AU/mL.
Time frame: Day 29
Part 1: Number of Participants With First Event of Centers for Disease Control and Prevention (CDC)-Defined COVID-19
CDC COVID-19 definition: the presence of at least 1 CDC listed symptom and positive reverse transcriptase polymerase chain reaction (RT-PCR) test on a respiratory sample.
Time frame: From 14 days after injection up to Day 365
Part 1: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs were recorded daily using electronic diaries (eDiaries). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to Day 7 (7-day follow-up after vaccination)
Part 3: Number of Participants With Solicited Local and Systemic ARs
Solicited ARs were recorded daily using eDiaries. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to Day 7 (7-day follow-up after vaccination)
Part 1: Number of Participants With Unsolicited Adverse Events (AEs)
An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to Day 28 (28-day follow-up after vaccination)
Part 3: Number of Participants With Unsolicited AEs
An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to Day 28 (28-day follow-up after vaccination)
Part 1: Number of Participants With Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs)
SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AEs leading to the withdrawal from study reported for this endpoint also include the AEs that led to death. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 up to Day 365
Part 3: Number of Participants With Any SAEs, MAAEs, AEs Leading to Withdrawal From Study, and AESIs
SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AEs leading to the withdrawal from study reported for this endpoint also include the AEs that led to death. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 up to Day 181
Part 1: GMs of Omicron BA.4/5 and Ancestral SARS-CoV-2 D614G
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL for Omicron BA.4/5. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for ancestral SARS-CoV-2 D614G.
Time frame: Days 91, 181, and 365
Part 1: SRR Against Omicron BA.4/5 and Ancestral SARS-CoV-2 D614G at Days 91, 181, and 365
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL for Omicron BA.4/5. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for ancestral SARS-CoV-2 D614G.
Time frame: Days 91, 181, and 365
Part 1: Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)
SARS-CoV-2 infection (symptomatic or asymptomatic) was defined as (1) negative binding antibody (bAb) level against SARS-CoV-2 nucleocapsid protein and negative RT-PCR at baseline that became positive bAb level against SARS-CoV-2 nucleocapsid protein post-baseline, or (2) positive RT-PCR post-baseline. Asymptomatic SARS-CoV-2 infection was characterized by the absence of COVID-19 symptoms.
Time frame: From 14 days after injection up to Day 365
Part 3: GM of Omicron XBB.1.5 in Unvaccinated Participants
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.
Time frame: Day 29
Part 3: GM of Omicron XBB.1.5 in All Study Participants
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.
Time frame: Day 29
Part 3: SRR Against Omicron XBB.1.5 in Unvaccinated Participants
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to last non-missing measurement on or before study vaccination day. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.
Time frame: Day 29
Part 3: SRR Against Omicron XBB.1.5 in All Study Participants
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to last non-missing measurement on or before study vaccination day. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.
Time frame: Day 29
| Milestone | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|---|---|
| Started | 5728 | 5725 | 1056 | 1044 |
| Received at least 1 dose of study drug | 5706 | 5710 | 1052 | 1039 |
| Per-protocol immunogenicity subset (ppis) | 623 | 568 | 994 | 967 |
| Solicited safety set | 5702 | 5705 | 1052 | 1039 |
| Completed | 5312 | 5373 | 991 | 967 |
| Not completed | 416 | 352 | 65 | 77 |
| Withdrew: Adverse event | 4 | 2 | 1 | 0 |
| Withdrew: Death | 7 | 11 | 0 | 1 |
| Withdrew: Lost to follow-up | 180 | 152 | 39 | 54 |
| Withdrew: Physician decision | 14 | 10 | 2 | 1 |
| Withdrew: Pregnancy | 2 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 181 | 157 | 17 | 15 |
| Withdrew: Other than specified | 4 | 4 | 2 | 1 |
| Withdrew: Randomized but not treated | 22 | 15 | 4 | 5 |
Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 103 arbitrary units (AU)/milliliter (mL) and ULOQ was 28571 AU/mL.
| AU/mL | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29 | 2340.9 ± 2167.0 | 1753.8 ± 1618.2 |
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL.
| percentage of participants | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Part 1: Seroresponse Rate (SRR) Omicron BA.4/5 at Day 29 | 79.9 ± 76.5 | 65.5 ± 61.4 |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL.
| AU/mL | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Part 1: GM of the Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) D614G at Day 29 | 10631.9 ± 9960.2 | 8576.5 ± 8012.5 |
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 10 AU/mL and ULOQ was 111433AU/mL.
| percentage of participants | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Part 1: SRR of Ancestral SARS-CoV-2 D641G at Day 29 | 83.6 ± 80.4 | 72.9 ± 69.0 |
CDC COVID-19 definition: the presence of at least 1 CDC listed symptom and positive reverse transcriptase polymerase chain reaction (RT-PCR) test on a respiratory sample.
| Participants | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Part 1: Number of Participants With First Event of Centers for Disease Control and Prevention (CDC)-Defined COVID-19 | 560 | 617 |
Solicited ARs were recorded daily using electronic diaries (eDiaries). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Part 1: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | 4571 | 4781 |
Solicited ARs were recorded daily using eDiaries. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|
| Part 3: Number of Participants With Solicited Local and Systemic ARs | 767 | 799 |
An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Part 1: Number of Participants With Unsolicited Adverse Events (AEs) | 706 | 683 |
An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|
| Part 3: Number of Participants With Unsolicited AEs | 73 | 76 |
SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AEs leading to the withdrawal from study reported for this endpoint also include the AEs that led to death. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| SAEs | 203 | 197 |
| MAAEs | 2165 | 2120 |
| AEs Leading to Withdrawal From Study | 11 | 13 |
| AESIs | 79 | 75 |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL for Omicron BA.4/5. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for ancestral SARS-CoV-2 D614G.
| AU/mL | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Omicron BA.4/5: Day 91 | 1513.2 (1400.9 to 1634.5) | 1137.8 (1049.8 to 1233.3) |
| Omicron BA.4/5: Day 181 | 1113.3 (1022.4 to 1212.3) | 863.7 (792.1 to 941.9) |
| Omicron BA.4/5: Day 365 | 753.3 (690.2 to 822.2) | 625.9 (572.8 to 684.0) |
| SARS-CoV-2 D614G: Day 91 | 6537.7 (6086.0 to 7023.0) | 5414.0 (5023.9 to 5834.3) |
| SARS-CoV-2 D614G: Day 181 | 4753.2 (4381.5 to 5156.5) | 3861.8 (3555.3 to 4194.6) |
| SARS-CoV-2 D614G: Day 365 | 2878.9 (2645.2 to 3133.3) | 2545.0 (2335.6 to 2773.2) |
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL for Omicron BA.4/5. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for ancestral SARS-CoV-2 D614G.
| percentage of participants | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Omicron BA.4/5: Day 91 | 59.5 (55.5 to 63.4) | 45.8 (41.6 to 50.1) |
| Omicron BA.4/5: Day 181 | 45.7 (41.4 to 50.0) | 37.1 (33.0 to 41.4) |
| Omicron BA.4/5: Day 365 | 30.0 (26.1 to 34.2) | 26.4 (22.6 to 30.6) |
| SARS-CoV-2 D614G Day 91 | 64.8 (60.8 to 68.6) | 52.9 (48.6 to 57.1) |
| SARS-CoV-2 D614G Day 181 | 45.6 (41.3 to 49.9) | 39.0 (34.8 to 43.4) |
| SARS-CoV-2 D614G Day 365 | 26.3 (22.5 to 30.4) | 25.4 (21.6 to 29.5) |
SARS-CoV-2 infection (symptomatic or asymptomatic) was defined as (1) negative binding antibody (bAb) level against SARS-CoV-2 nucleocapsid protein and negative RT-PCR at baseline that became positive bAb level against SARS-CoV-2 nucleocapsid protein post-baseline, or (2) positive RT-PCR post-baseline. Asymptomatic SARS-CoV-2 infection was characterized by the absence of COVID-19 symptoms.
| Participants | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 |
|---|---|---|
| Part 1: Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic) | 1249 | 1290 |
SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AEs leading to the withdrawal from study reported for this endpoint also include the AEs that led to death. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|
| SAEs | 15 | 20 |
| MAAEs | 140 | 126 |
| AEs Leading to Withdrawal From Study | 1 | 1 |
| AESIs | 2 | 5 |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.
| AU/mL | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|
| Part 3: GM of Omicron XBB.1.5 in Unvaccinated Participants | 2571.1 (2247.1 to 2941.7) | 1896.8 (1647.4 to 2183.9) |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.
| AU/mL | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|
| Part 3: GM of Omicron XBB.1.5 in All Study Participants | 2747.3 (2552.4 to 2957.1) | 2027.0 (1881.6 to 2183.7) |
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to last non-missing measurement on or before study vaccination day. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.
| percentage of participants | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|
| Part 3: SRR Against Omicron XBB.1.5 in Unvaccinated Participants | 91.1 (87.7 to 93.8) | 87.0 (83.0 to 90.4) |
Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to last non-missing measurement on or before study vaccination day. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.
| percentage of participants | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|
| Part 3: SRR Against Omicron XBB.1.5 in All Study Participants | 88.3 (86.1 to 90.2) | 81.2 (78.6 to 83.6) |
Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs leading to study discontinuation: Day 1 up to Day 365. Other (non-serious) AEs: up to 28 days after study injection, unless they met criteria for AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: mRNA-1283.222 | 9/5,728 (0.2%) | 203/5,706 (3.6%) | 607/5,706 (10.6%) |
| Part 1: mRNA-1273.222 | 11/5,725 (0.2%) | 197/5,710 (3.5%) | 636/5,710 (11.1%) |
| Part 3: mRNA-1283.815 | 0/1,056 (0%) | 15/1,052 (1.4%) | 21/1,052 (2%) |
| Part 3: mRNA-1273.815 | 1/1,044 (0.1%) | 20/1,039 (1.9%) | 16/1,039 (1.5%) |
| Event | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 6/5706 | 11/5710 | 1/1052 | 3/1039 |
| Cardiac arrestCardiac disorders | 2/5706 | 1/5710 | 0/1052 | 2/1039 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/5706 | 1/5710 | 0/1052 | 2/1039 |
| Suicidal ideationPsychiatric disorders | 3/5706 | 0/5710 | 2/1052 | 0/1039 |
| Tibia fractureInjury, poisoning and procedural complications | 0/5706 | 1/5710 | 2/1052 | 1/1039 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 10/5706 | 6/5710 | 0/1052 | 0/1039 |
| Myocardial infarctionCardiac disorders | 7/5706 | 6/5710 | 0/1052 | 0/1039 |
| Atrial fibrillationCardiac disorders | 4/5706 | 7/5710 | 0/1052 | 0/1039 |
| Acute kidney injuryRenal and urinary disorders | 6/5706 | 2/5710 | 0/1052 | 0/1039 |
| AppendicitisInfections and infestations | 4/5706 | 0/5710 | 1/1052 | 1/1039 |
| Event | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 607/5706 | 636/5710 | 21/1052 | 16/1039 |
The Safety Set included all randomized participants who received study drug.
| Age, Categorical(Participants) | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 | Total |
|---|---|---|---|---|---|
| <=18 years | 497 | 495 | 502 | 495 | 1989 |
| Between 18 and 65 years | 3575 | 3575 | 453 | 455 | 8058 |
| >=65 years | 1634 | 1640 | 97 | 89 | 3460 |
| Sex: Female, Male(Participants) | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 | Total |
|---|---|---|---|---|---|
| Female | 3120 | 3079 | 559 | 537 | 7295 |
| Male | 2586 | 2631 | 493 | 502 | 6212 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 769 | 741 | 230 | 253 | 1993 |
| Not Hispanic or Latino | 4860 | 4863 | 815 | 777 | 11315 |
| Unknown or Not Reported | 77 | 106 | 7 | 9 | 199 |
| Race/Ethnicity, Customized(Participants) | Part 1: mRNA-1283.222 | Part 1: mRNA-1273.222 | Part 3: mRNA-1283.815 | Part 3: mRNA-1273.815 | Total |
|---|---|---|---|---|---|
| Race — White | 4670 | 4711 | 690 | 700 | 10771 |
| Race — Black or African American | 640 | 634 | 288 | 260 | 1822 |
| Race — Asian | 225 | 183 | 21 | 18 | 447 |
| Race — American Indian or Alaska Native | 20 | 26 | 5 | 8 | 59 |
| Race — Native Hawaiian or Other Pacific Islander | 9 | 6 | 1 | 3 | 19 |
| Race — Multiple | 81 | 94 | 40 | 43 | 258 |
| Race — Other | 20 | 20 | 2 | 2 | 44 |
| Race — Not Reported | 36 | 26 | 5 | 3 | 70 |
| Race — Unknown | 5 | 10 | 0 | 2 | 17 |
Showing the first 100 of 230 sites across 4 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2023 to primary completion in Apr 2025, 24 months.
Results were first posted in May 2026, 1 year after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 24 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elasomeran/Davesomeran